Clinical Trials Logo

Diffuse Intrinsic Pontine Glioma clinical trials

View clinical trials related to Diffuse Intrinsic Pontine Glioma.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06333899 Not yet recruiting - Glioblastoma Clinical Trials

Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion

Start date: September 1, 2024
Phase: Early Phase 1
Study type: Interventional

The goal of this study is to determine the response of the study drug loratinib in treating children who are newly diagnosed high-grade glioma with a fusion in ALK or ROS1. It will also evaluate the safety of lorlatinib when given with chemotherapy or after radiation therapy.

NCT ID: NCT06161974 Not yet recruiting - High Grade Glioma Clinical Trials

Study of Olutasidenib and Temozolomide in HGG

Start date: June 2024
Phase: Phase 2
Study type: Interventional

The goal of this study is to determine the efficacy of the study drug olutasidenib to treat newly diagnosed pediatric and young adult patients with a high-grade glioma (HGG) harboring an IDH1 mutation. The main question the study aims to answer is whether the combination of olutasidenib and temozolomide (TMZ) can prolong the life of patients diagnosed with an IDH-mutant HGG.

NCT ID: NCT06093165 Not yet recruiting - Clinical trials for Diffuse Intrinsic Pontine Glioma

RE-irradiation of Diffuse MIdline Glioma paTients

REMIT
Start date: October 2023
Phase: N/A
Study type: Interventional

The REMIT (RE-irradiation of diffuse MIdline glioma paTients) study evaluates safety and the palliative efficacy of re-irradiation of patients with diffuse midline glioma (DMG). The study will introduce a standard re-irradiation treatment schedule for DMG patients who have progressed following primary treatment.

NCT ID: NCT05843253 Not yet recruiting - Glioblastoma Clinical Trials

Study of Ribociclib and Everolimus in HGG and DIPG

Start date: May 30, 2024
Phase: Phase 2
Study type: Interventional

The goal of this study is to determine the efficacy of the study drugs ribociclib and everolimus to treat pediatric and young adult patients newly diagnosed with a high-grade glioma (HGG), including DIPG, that have genetic changes in pathways (cell cycle, PI3K/mTOR) that these drugs target. The main question the study aims to answer is whether the combination of ribociclib and everolimus can prolong the life of patients diagnosed with HGG, including DIPG.

NCT ID: NCT05839379 Not yet recruiting - Glioblastoma Clinical Trials

Targeted Pediatric High-Grade Glioma Therapy

Start date: May 30, 2024
Phase:
Study type: Observational

The goal of this study is to perform genetic sequencing on brain tumors from children, adolescents, and young adult patients who have been newly diagnosed with a high-grade glioma. This molecular profiling will decide if patients are eligible to participate in a subsequent treatment-based clinical trial based on the genetic alterations identified in their tumor.

NCT ID: NCT05096481 Not yet recruiting - High Grade Glioma Clinical Trials

PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma

Start date: April 15, 2024
Phase: Phase 2
Study type: Interventional

This study will address the question of whether targeting CMV antigens with PEP-CMV can serve as a novel immunotherapeutic approach in pediatric patients with newly-diagnosed high-grade glioma (HGG) or diffuse intrinsic pontine glioma (DIPG) as well as recurrent medulloblastoma (MB). PEP-CMV is a vaccine mixture of a peptide referred to as Component A. Component A is a synthetic long peptide (SLP) of 26 amino acid residues from human pp65. The SLPs encode multiple potential class I, class II, and antibody epitopes across several haplotypes. Component A will be administered as a stable water:oil emulsion in Montanide ISA 51. Funding Source - FDA OOPD